The 10-year U.S. Treasury yield has reached 5%, the highest level in nearly 20 years since the post-Great Financial Crisis period. This rise improves the expected returns for high-quality fixed income investments, favoring businesses that generate strong cash flow and are self-funded. However, it puts pressure on speculative, long-duration growth stocks and may challenge traditional stock-bond diversification strategies as well as risk-parity portfolios. Investors may need to adjust their portfolios to account for these changing dynamics in the fixed income and equity markets.
The 10-year U.S. Treasury yield reaching 5% sets a backdrop for fixed income and equity market dynamics. For readers following U.S. stocks, here is Pluang's market snapshot as of Sep 16, 2026 04:03 WIB: out of 150 priced US stocks tradable on Pluang, 57 rose and 92 fell today. Notable movers include OPEN at USD 2.64 with a 1-day change of -5.38%, CVNA at USD 67.07 down 5.36%, and SE at USD 103.40 down 4.86%.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
